Clinical Trial Update: Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

View source ↗

Summary

Registry update shows that the Translarna (ataluren) study in nonsense mutation Duchenne muscular dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Muscular Dystrophy, Duchenne | Status: COMPLETED